Targeting the recurrent Rac1P29S neoepitope in melanoma with heterologous high-affinity T cell receptors

2Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Recurrent neoepitopes are cancer-specific antigens common among groups of patients and therefore ideal targets for adoptive T cell therapy. The neoepitope FSGEYIPTV carries the Rac1P29S amino acid change caused by a c.85C>T missense mutation, which is the third most common hotspot mutation in melanoma. Here, we isolated and characterized TCRs to target this HLA-A*02:01-binding neoepitope by adoptive T cell therapy. Peptide immunization elicited immune responses in transgenic mice expressing a diverse human TCR repertoire restricted to HLA-A*02:01, which enabled isolation of high-affinity TCRs. TCR-transduced T cells induced cytotoxicity against Rac1P29S expressing melanoma cells and we observed regression of Rac1P29S expressing tumors in vivo after adoptive T cell therapy (ATT). Here we found that a TCR raised against a heterologous mutation with higher peptide-MHC affinity (Rac2P29L) more efficiently targeted the common melanoma mutation Rac1P29S. Overall, our study provides evidence for the therapeutic potential of Rac1P29S-specific TCR-transduced T cells and reveal a novel strategy by generating more efficient TCRs by heterologous peptides.

Cite

CITATION STYLE

APA

Immisch, L., Papafotiou, G., Gallarín Delgado, N., Scheuplein, V., Paschen, A., Blankenstein, T., & Willimsky, G. (2023). Targeting the recurrent Rac1P29S neoepitope in melanoma with heterologous high-affinity T cell receptors. Frontiers in Immunology, 14. https://doi.org/10.3389/fimmu.2023.1119498

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free